Page 44 - 2021_03-Haematologica-web

L.-A. Sutton et al.
data and/or provided samples and clinical data; KS and RR directed the study and wrote the paper.
Funding
LAS and RR have received funding from the Swedish Cancer Society, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Karolinska Institutet, Karolinska University Hospital, and Radiumhemmets Forskningsfonder, Stockholm. PG has received funding from the Associazione Italiana per la Ricerca sul Cancro – AIRC, Milano, Italy (Investigator Grant #20246 and Special Program on Metastatic Disease – 5 per mille #21198), and ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2016 (project #179 NOVEL), project code (MIS) 5041673. JCS has received fund- ing from Bloodwise (11052, 12036), the Kay Kendall Leukaemia Fund (873), Cancer Research UK (C34999/A18087, ECMC C24563/A15581) and the Bournemouth Leukaemia Fund. KS has received funding from the Hellenic Precision Medicine Network in Oncology and the KRIPIS action supported by the General Secretariat for Research and Technology of Greece. SP has received funding from the
Czech Science Foundation GA19-15737S and was also sup- ported by the Ministry of Health of the Czech Republic, Grant No. NV19-03-00091. ET and SS were supported by the DFG (SFB1074, project B2) and the EU (FIRE CLL). ET also received funding from Else Kröner-Fresenius-Stiftung (2010_Kolleg24), EC (01KT1601, FIRE CLL), BMBF (031L0076C PRECISe) and Deutsche Forschungsgemeinschaft (SFB 1074 projects B1, B2). EC has received funding from the Instituto de Salud Carlos III (PMP15/00007), CIBERONC, “La Caixa” Foundation (grant CLLEvolution-HR17-00221).
Acknowledgments
We acknowledge the CF Genomics CEITEC MU supported by the NCMG research infrastructure (LM2015091 funded by MEYS CR) for their support with obtaining scientific data pre- sented in this paper. For the Swedish center, sequencing was per- formed at Clinical Genomics, Uppsala, and the SNP&SEQ Technology Platform, SciLifeLab at Uppsala University, a national infrastructure supported by the Swedish Research Council (Council for Research Infrastructures [VRRFI]) and the Knut and Alice Wallenberg Foundation.
References
1. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational acti- vation. J Exp Med. 2011;208(7):1389-1401.
2.Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recur- rent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
3.Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011;44(1):47-52.
4.Wang LL, Lawrence MS, Wan YZ, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-2506.
5. Puente XS, Bea S, Valdes-Mas R, et al. Non- coding recurrent mutations in chronic lym- phocytic leukaemia. Nature. 2015; 526(7574):519-524.
6. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolu- tion in progression and relapse. Nature. 2015;526(7574):525-530.
7.Sutton LA, Rosenquist R. Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. Haematologica. 2015;100(1):7-16.
8.Mansouri L, Sutton LA, Ljungstrom V, et al. Functional loss of I kappa B epsilon leads to NF-kappa B deregulation in aggressive chronic lymphocytic leukemia. J Exp Med. 2015;212(6):833-843.
9.Ljungstrom V, Cortese D, Young E, et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood. 2016;127(8):1007-1016.
10. Young E, Noerenberg D, Mansouri L, et al. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia. 2017;31(7):1547-1554.
11. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lympho- cytic leukemia. J Clin Oncol. 2010;28(29): 4473-4479.
12.Del Giudice I, Rossi D, Chiaretti S, et al.
NOTCH1 mutations in+12 chronic lympho- cytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcription- al profiling and refine the intermediate prog- nosis of+12 CLL. Haematologica. 2012; 97(3):437-441.
13. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with flu- darabine chemorefractoriness in TP53 wild- type chronic lymphocytic leukemia. Blood. 2012;119(12):2854-2862.
14. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identi- fies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013; 121(8):1403-1412.
15.Strefford JC, Sutton LA, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia. 2013;27(11):2196-2199.
16. Cortese D, Sutton LA, Cahill N, et al. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia. 2014;28(3):710-713.
17. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28(1):108-117.
18. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247- 3254.
19. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329-336.
20.Sutton LA, Young E, Baliakas P, et al. Different spectra of recurrent gene muta- tions in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica. 2016;101(8):959- 967.
21.Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated sub- clones in chronic lymphocytic leukemia. Blood. 2014;123(14):2139-2147.
22. Malcikova J, Stano-Kozubik K, Tichy B, et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lym- phocytic leukemia. Leukemia. 2015;29(4): 877-885.
23. Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127(17):2122-2130.
24. Brieghel C, Kinalis S, Yde CW, et al. Deep targeted sequencing of TP53 in chronic lym- phocytic leukemia: clinical impact at diagno- sis and at time of treatment. Haematologica. 2019;104(4):789-796.
25.Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution pat- terns. Blood. 2012;120(20):4191-4196.
26.Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal muta- tions in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
27.Rasi S, Khiabanian H, Ciardullo C, et al. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2016;101(4):e135-e138.
28. Nadeu F, Clot G, Delgado J, et al. Clinical impact of the subclonal architecture and mutational complexity in chronic lympho- cytic leukemia. Leukemia. 2018;32(3):645- 653.
29. Leeksma AC, Taylor J, Wu B, et al. Clonal diversity predicts adverse outcome in chron- ic lymphocytic leukemia. Leukemia. 2019; 33(2):390-402.
30. Mansouri L, Sutton LA, Ljungstrom V, et al. Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia. Leukemia. 2014;28(3):694-696.
31. Sutton LA, Ljungstrom V, Mansouri L, et al. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high- throughput yet tailored approach will facili- tate implementation in a clinical setting. Haematologica. 2015;100(3):370-376.
32. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications
690
haematologica | 2021; 106(3)